CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine
Congratulations to Professor Janette Vardy (University of Sydney) and Doctor Haryana Dhillon (University of Sydney) who were successful in their funding application to the National Health and Medical Research Council (NHMRC) to continue the CCTG led CHALLENGE (CO.21) trial in Australia
As we embark on a new year, it is time to reflect on what we have accomplished together this year and what 2019 will bring. It has been a busy year with continued growth and expansion across our national and international networks.
Congratulations to the researchers who presented abstracts at the American Society of Hematology Annual Meeting (ASH) and San Antonio Breast Cancer Symposium.
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative hosted a Clinical Trial Workshop in Hong Kong December 8-9th 2018. Formed in 2015, CommNETs operates within the auspices of the Canadian Cancer Trials Group and the Australasian Gastro-intestinal Trials Group to bring together researchers, clinicians, and consumers from Australia, New Zealand and Canada to improve the outcomes of patients with Neuroendocrine Tumours (NETs).
The Pharmacist Network is actively seeking volunteers as Pharmacist Representatives for the Breast and Gastrointestinal Disease Site Committees. Participation in these opportunities earns volunteers a fully funded invitation to the annual CCTG Spring Meeting in Toronto.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at:
When it comes to cancer, a lot can happen in 30 minutes. Someone can have a life-changing appointment with their doctor, receive a supportive phone call from a peer or start cancer treatment.
